Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421257 | 1.00 | PDPK1 (0.55) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30130746 | 0.82 | HTR2C (0.40) | PDPK1 | |
| SCHEMBL4972049 | 0.82 | HTR2C (0.40) | PDPK1 | |
| SCHEMBL16421280 | 0.81 | SLC6A2 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13080424 | 0.81 | SLC6A2 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13080425 | 0.81 | SLC6A2 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2581504 | 0.78 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2578485 | 0.78 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13223488 | 0.78 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2402634 | 0.78 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455075-A1 | Combinations of Eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, & Cognitive Disorders | Sepracor Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2007006003-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | SEPRACOR INC. (US) | 2007-01-11 | — | — | WO | disclosed |